Kevin T. Conroy - Aug 2, 2021 Form 4 Insider Report for EXACT SCIENCES CORP (EXAS)

Role
President and CEO, Director
Signature
/s/ Kevin T. Conroy by Mark R. Busch, attorney-in-fact
Stock symbol
EXAS
Transactions as of
Aug 2, 2021
Transactions value $
-$2,146,775
Form type
4
Date filed
8/4/2021, 04:36 PM
Previous filing
Jul 6, 2021
Next filing
Sep 3, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EXAS Common Stock Sale -$2.15M -20K -2.71% $107.50 717K Aug 2, 2021 Direct F1, F2
holding EXAS Common Stock 26.5K Aug 2, 2021 Held in 401(k) Plan
holding EXAS Common Stock 21.7K Aug 2, 2021 Held in Grantor Retained Annuity Trust
holding EXAS Common Stock 21.7K Aug 2, 2021 Held in Grantor Retained Annuity Trust
holding EXAS Common Stock 21.7K Aug 2, 2021 Held in Grantor Retained Annuity Trust
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sale reported in this field was effected pursuant to a Rule 10b5-1 trading plan, which trading plan was disclosed via Form 8-K filed by Exact Sciences Corporation with the U.S. Securities and Exchange Commission on November 27, 2020.
F2 In addition to the shares of Common Stock reported on this Form 4, which total 809,037 shares, Mr. Conroy also holds, in the aggregate, an additional 1,207,918 vested and unvested options to purchase shares of Common Stock and restricted stock units, with each restricted stock unit representing a contingent right to receive one share of Common Stock.